Somatostatin Receptor (SSTR) Scintigraphy in Patients with Osteosarcoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 5, 2003, Pages 847-851

  Ferrari, Stefano ^a   Dondi, Maurizio ^b   Fanti, Stefano ^b   Zoboli, Stefania ^b   Giacomini, Stefano ^a   Mercuri, Mario ^a   Bacci, Gaetano ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b MAGGIORE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; IFOSFAMIDE; LACTATE DEHYDROGENASE; MEDRONATE TECHNETIUM TC 99M; METHOTREXATE; PENTETREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER LOCALIZATION; CHEMOSENSITIVITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG MEGADOSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGING SYSTEM; ISOTOPE LABELING; LUNG METASTASIS; MALE; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; TUMOR VOLUME;

EID: 0242581453     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803770418391     Document Type: Article

References (20)

1. Campanacci M. Bone and Soft Tissue Tumors, 2nd ed. Wien, New York: Springer-Verlag, 1999.
2. Ferrari S, Briccoli A, Mercuri M, et al. Post relapse survival in osteosarcoma of the extremity: Prognostic factors for long term survival. J Clin Oncol 2003;21:710.
3. Fagioli F, Aglietta M, Tienghi A, et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: An Italian Sarcoma Group study. J Clin Oncol 2002;20:2150.
4. Meyers PA, Heller G, Healey JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993;11:449.
5. Bacci G, Mercuri M, Briccoli A, et al. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. Cancer 1997;79:245.
6. Hejna M, Schmidinger M, Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: Much ado about nothing? Ann Oncol 2002;13:653.
7. Pinski J, Schally AV, Halmos G, et al. Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice. Int J Cancer 1996;65:870.
8. Brazeau P, Vale W, Burgus R, et al. Hypotalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77.
9. Lamberts SWJ, Koper JW, Reubi JC. Potential role of somatostatin analogues in the treatment of cancer. Eur J Clin Invest 1987;17:281.
10. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst-1-sst-5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836.
11. Hofland LJ, Lamberts SWJ. Somatostatin receptor subtype expression in human tumors. Ann Oncol 2001;12(suppl. 2):S31.
12. Palmieri G, Montella L, Apice G, et al. RT-PCR analysis of somatostatin receptors expression in human soft tissue sarcomas. Proceedings of the American Society of Clinical Oncology (ASCO). 2002;21:407a (abstr. 1625).
13. Reubi JC, Waser B, Laissue JA, Gebbers JO. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: In vitro identification. Cancer Res 1996;56:1922.
14. Friedberg JW, Van den Abbeele AD, Kehoe K, et al. Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma. Cancer 1999;86:1621.
15. Krenning EP, Bakker WH, et al. Somatostatin receptor scintigraphy with [111-In-DPTA-D-Phe 1]-octreotide in man: Metabolism, dosimetry and comparison with [123-I-Tyr 3]-octreotide. J Nucl Med 1992;33:652.
16. Bombardieri E, Maccauro M, de Deckere E, et al. Nuclear medicine imaging of neuroendocrine tumors. Ann Oncol 2001;12(suppl. 2):S51.
17. Reichlin S. Secretion of somatostatin and its physiologic function. J Lab Clin Med 1987;109:320.
18. Pollak MN, Polychronakos C, Richard M. Insuline-like growth factor I: A potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst 1990;82:301.
19. Pollak MN, Sem AW, Richard M, et al. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst 1992;84:966.
20. Mansky PJ, Liewehr DJ, Steinberg SM, et al. Treatment of metastatic osteosarcoma with somatostatin analog Oncolar: Significant reduction of Insulin-like growth Factor-1 serum levels. J Pediatr Hematol Oncol 2002;24:440.